GP
Therapeutic Areas
Dr. Reddy's Laboratories Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lenalidomide (Generic Revlimid) | Multiple Myeloma | Approved |
| Esomeprazole (Generic Nexium) | GERD | Approved |
| Glatiramer Acetate (Generic Copaxone) | Multiple Sclerosis | Approved |
| Rituximab Biosimilar | Oncology/Autoimmune | Approved |
| Trastuzumab Biosimilar | Breast Cancer | Approved |
| Pegfilgrastim Biosimilar | Neutropenia | Approved |
| DRL-17822 | Oncology | Phase 2 |
Leadership Team at Dr. Reddy's Laboratories
EI
Erez Israeli
CEO - North America Generics & Global Head of API business
PA
Parag Agarwal
CFO
MN
M.V. Narasimham
CEO - Emerging Markets & India
DS
Deepak Sapra
CEO - API & Services
RG
Richa Gangopadhyay
Chief Human Resources Officer